Core Viewpoint - The launch of patient enrollment for the clinical cohort study of brain-machine interfaces (BMIs) in China marks a significant step towards the clinical application of implanted BMIs, with 2025 being a pivotal year for the technology's commercialization in the country [1][2]. Industry Development - The clinical cohort study led by Huashan Hospital and Beijing Xuanwu Hospital aims to validate the effectiveness and safety of implanted BMI treatment solutions [1]. - The NEO semi-invasive BMI, developed in collaboration with Tsinghua University and Borui Kang Medical Technology, is set to begin large-scale clinical trials in 2025, targeting 30 to 50 patients with spinal cord injuries [2]. - The market for BMIs in China is projected to grow from 3.2 billion yuan in 2024 to 5.58 billion yuan by 2027, with an average annual growth rate of around 20% [3]. Commercialization Potential - The commercialization of implanted BMIs is expected to prioritize medical rehabilitation applications in the short term, while expanding into consumer scenarios such as smart driving and virtual reality in the long term [4]. - Policies and local government initiatives are actively supporting the development of the BMI industry, with specific pricing projects established for invasive BMI procedures [3]. Company Strategies - Companies like Chengyi Tong and Lihua Kechuang are focusing on dual-track strategies involving both invasive and non-invasive BMIs, emphasizing deep collaborations with renowned universities for technological advancements [6]. - Lihua Kechuang is investing in the development of fully implanted wireless BMI systems through its partnerships with startups in the field [6]. - Companies are encouraged to increase R&D investments to overcome key technical challenges and to collaborate closely with hospitals to expedite clinical trials and product registrations [7].